Clofazimine

氯法齐明

Report date: 2022/05/11 12:43:19
NMEQIDP

Base Information

Drug NameClofazimine
Drug Alias NameClofazimina氨苯吩嗪氯苯吩嗪ClofaziminumLampren +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA inhibitors
TargetsDNA
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lung DiseasesCryptosporidiosis +[6] 
Global Approved IndicationsLeprosy
Approved Indications in ChinaLeprosy
Original Approved Country/TerritoryMainland China
Original Approved Date1985/01/01
Country/TerritoryUnited StatesTaiwanNetherlands +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical CenterOregon Health And Science UniversityShanxi Liye Pharmaceutical Co Ltd
Inactive CompaniesMannKind CorpNovartis Pharma AgUniversity Of Washington +[4] 
Active IndicationsMycobacterium avium-intracellulare InfectionLeprosyMycobacterium Infections, Nontuberculous
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Lung DiseasesCryptosporidiosis

Other Information

ATC CodeJ04BA01
Related LinksWikipediaDrugBankKEGG